Tango Therapeutics Incorporated is a biotechnology company that develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 to treat cancers with methylthioadenosine phosphorylase deletions. The company is also developing Ubiquitin-specific protease 1, an inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers, and Target 3 for STK11-mutant cancers. Tango Therapeutics was founded in 2017 and is headquartered in Cambridge, MA.
What is Tango Therapeutics's quote symbol?
What is the 52 week high and low for Tango Therapeutics (NASDAQ: TNGX)?
How much is Tango Therapeutics stock worth today?
How much is Tango Therapeutics's stock price per share?
What is Tango Therapeutics's Market Cap?